Reduced Immunosuppressive Properties of Axitinib in Comparison with Other Tyrosine Kinase Inhibitors*

[D.ap]

Reduced Immunosuppressive Properties of Axitinib in Comparison with Other Tyrosine Kinase Inhibitors*
Authors
Background: Targeted therapies with tyrosine kinase inhibitors (TKIs) are used for the treatment of advanced renal cell carcinoma.
Results: T cell activation is less affected in the presence of axitinib compared with other TKIs.
Conclusion: Axitinib might be better suited to be combined with immunotherapy than sorafenib.
Significance: Learning how TKIs manipulate T cells is crucial for understanding TKI-mediated effects on the immune system.


http://www.jbc.org/content/288/23/16334.short